Cabaletta Bio (CABA) Interest Expenses (2024 - 2025)
Cabaletta Bio's quarterly Interest Expenses came in at $555000.0 in Q4 2025, down 25.8% year-on-year from $748000.0 in Q4 2024, and down 4.97% quarter-over-quarter from $584000.0 in Q3 2025.
Cabaletta Bio has reported Interest Expenses for 2 years, with the latest figure at $555000.0 in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses fell 25.8% year-over-year to $555000.0; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (up 167.91% YoY), and the FY2025 full-year result was $2.0 million, up 167.91% from the prior year.
- Interest Expenses for Q4 2025 stood at $555000.0, down from $584000.0 in the prior quarter.
- The five-year high for Interest Expenses was $748000.0 in Q4 2024, with the low at $294000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | 555,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 555,000.00 |
| Dec 31, 2025 | 555,000.00 |
| Sep 30, 2025 | 584,000.00 |
| Sep 30, 2025 | 584,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Mar 31, 2025 | 294,000.00 |
| Mar 31, 2025 | 294,000.00 |
| Dec 31, 2024 | 748,000.00 |
| Dec 31, 2024 | 748,000.00 |